Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1995 3
1997 1
1998 4
1999 2
2000 2
2001 1
2002 3
2003 7
2004 13
2005 4
2006 6
2007 7
2008 6
2009 9
2010 6
2011 2
2012 10
2013 4
2014 6
2015 3
2016 6
2017 3
2018 2
2019 7
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 22184649

114 results
Results by year
Filters applied: . Clear all
Page 1
Use of palivizumab in primary practice.
Perrin KM, Bégué RE. Perrin KM, et al. Pediatrics. 2012 Jan;129(1):55-61. doi: 10.1542/peds.2010-2991. Epub 2011 Dec 19. Pediatrics. 2012. PMID: 22184649
Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis.
Mansbach J, Kunz S, Acholonu U, Clark S, Camargo CA Jr. Mansbach J, et al. Pediatr Emerg Care. 2007 Jun;23(6):362-7. doi: 10.1097/01.pec.0000278406.75815.d3. Pediatr Emerg Care. 2007. PMID: 17572518
The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.
Afghani B, Ngo T, Leu SY, Wu FL, Cecilio M, Aron-Johnson P, Zeitany R, Sills J, Amin A. Afghani B, et al. Pediatr Infect Dis J. 2006 Nov;25(11):1019-24. doi: 10.1097/01.inf.0000243164.47048.4b. Pediatr Infect Dis J. 2006. PMID: 17072124
Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Weiner LB, et al. J Med Econ. 2012;15(5):997-1018. doi: 10.3111/13696998.2012.672942. Epub 2012 Mar 21. J Med Econ. 2012. PMID: 22435648
Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD, Bao W, Holloway J, Mann J, Rye AK, Brown DE 3rd. Chadha AD, et al. South Med J. 2012 Aug;105(8):399-404. doi: 10.1097/SMJ.0b013e31825ea57d. South Med J. 2012. PMID: 22864095
Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J; Palivizumab Outcomes Registry Group. Frogel M, et al. Pediatr Infect Dis J. 2008 Oct;27(10):870-3. doi: 10.1097/INF.0b013e318174e0c4. Pediatr Infect Dis J. 2008. PMID: 18776822
Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
Lundeen K, Pfeiffenberger T, Jacobson Vann J, O'Brien T, Sampson C, Wegner S. Lundeen K, et al. J Manag Care Pharm. 2013 Mar;19(2):115-24. doi: 10.18553/jmcp.2013.19.2.115. J Manag Care Pharm. 2013. PMID: 23461427
Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Mahadevia PJ, et al. J Med Econ. 2012;15(5):987-96. doi: 10.3111/13696998.2012.690013. Epub 2012 May 10. J Med Econ. 2012. PMID: 22574798
From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
Committee on Infectious Diseases. Committee on Infectious Diseases. Pediatrics. 2009 Dec;124(6):1694-701. doi: 10.1542/peds.2009-2345. Epub 2009 Sep 7. Pediatrics. 2009. PMID: 19736258
Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
Elhassan NO, Stevens TP, Sorbero ME, Dick AW, Guillet R, Hall CB. Elhassan NO, et al. Pediatr Infect Dis J. 2003 Nov;22(11):939-43. doi: 10.1097/01.inf.0000095300.31563.f7. Pediatr Infect Dis J. 2003. PMID: 14614363
114 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback